AZN logo
AstraZeneca PLC
AZN
168.10 (1.22%) 2.04
Market cap
$260.73(B)
Earnings date
Oct-30-2026
Category
Sector
Health Care
Industry
Pharmaceuticals
AstraZeneca PLC a biopharmaceutical company focuses on the discovery development manufacture and commercialization of prescription medicines. The company offers Imjudo Datroway Iressa Tagrisso Imfinzi Lynparza Calquence Enhertu Orpathys Truqap Zoladex Faslodex Crestor Andexxa Onglyza Symlin XIGDUO XR Atacand Atacand HCT Atacand Plus Farxiga/Forxiga Plendil Modip Splendil Munobal Flodil Tenormin Tenormine Prenormine Atenol Zestril Brilinta/Brilique Komboglyze Qtern Wainua Byetta Lokelma Seloken ZOK Toprol-XL Betaloc ZOK XIGDUO Accolate Accoleit Vanticon Bricanyl Respules Eklira Genuair/Tudorza/Bretaris Pulmicort Turbuhaler Symbicort Turbuhaler Airsupra Bricanyl Turbuhaler Fasenra Rhinocort Tezspire Bevespi Aerosphere Daliresp/Daxas Oxis Turbuhaler Saphnelo Breztri Aerosphere Duaklir Genuair Pulmicort Respules and Symbicort pMDI. It also provides Beyfortus Kavigale Evusheld Fluenz/FluMist Synagis Kanuma Ultomiris Koselugo Voydeya Soliris Strensiq Nexium and other medicines. The company offers its products for ocology cardiovascular renal and metabolism respiratory & immunology vaccines and immune and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom the Americas rest of Europe Asia Africa and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge the United Kingdom.
EV: $288.04(B)
Total Equity: $50.37(B)
Debt/Equity: 0.64
Dividend/share: $3.2
Div. yield: 1.92%
P/E: 24.94
Forward P/E: 16.35
P/FCF: 24.43
P/S: 4.25
P/B: 5.18
EPS: $6.7
EPS (fwd): $10.3
FCF/share: $6.9
Revenue/share: $39.6
Book value/share: $32.4
ROIC: 12.5%
ROA: 8.6%
ROE: 21.7%
Margins: Gross | Op. | Net
81.7% | 22.0% | 17.0%
0.0%of Portfolio
My holdings
Day change
Total change
PEvaluation
35%
$109
Valuation summary
Min
Max
Average
Median
Valuation comparison
Current price$168
Quality checklist score
5/8
Based on your selected metrics.
ROIC > 10% Debt/Equity < 1 Net Margin > 10% Past Net Income CAGR > 0% Est. EPS Growth > 5%
5Y Shares Out Change < 0% Current Ratio > 1 Quick Ratio > 1

TTM Financials

Income (TTM)

RevenueGrossNet
Revenue$61.37(B)
Gross profit$50.13(B)
EBITDA$19.90(B)
Net income$10.45(B)
Gross margin81.7%
Operating margin22.0%
Net margin17.0%
Shares outstanding1.55(B)

Balance sheet

Cash & ST inv.Other ST assetsLong term assetsCurrent liabilitiesLong term debtOther LT liabilitiesEquity
Total assets$115.83(B)
Current assets$27.96(B)
Total liabilities$65.46(B)
Current liabilities$31.55(B)
Cash & Short-term inv.$4.97(B)
Long-term debt$23.69(B)
Total intangibles$58.90(B)
PP&E$16.30(B)

Cash flow (TTM)

CFOCFICFF
FCF$10.67(B)
CapEx$-3.03(B)
Dividends paid$-4.78(B)
Stock issued$44.00(M)
Stock repurchased$-690.00(M)
Stock-based comp.$719.00(M)
Debt issued$2.95(B)
Debt repaid$-4.84(B)

Per share data (TTM)

Price
Price
$168
Income
Revenue
$39.64.2x|23.6%
Gross profit
$32.35.2x|19.2%
Earnings (EPS)
$6.7424.9x|4.0%
Cash flow
FCF
$6.8824.4x|4.1%
Stock-based comp.
$0.46362.6x|0.3%
CapEx
$1.9586.0x|1.2%
Dividend
$3.2352.0x|1.9%
Balance sheet
Total assets
$74.72.3x|44.4%
Total liabilities
$42.24.0x|25.1%
Book value
$32.45.2x|19.3%
Cash & ST inv.
$3.2052.5x|1.9%
Debt
$15.311.0x|9.1%
Forward earnings
EPS FY+1
$10.316.4x|6.1%
EPS FY+2
$11.414.7x|6.8%
EPS FY+3
$12.713.2x|7.6%
EPS FY+4
$14.411.7x|8.6%
EPS FY+5
$16.010.5x|9.5%
Forward FCF
FCF FY+1
$5.6529.8x|3.4%
FCF FY+2
$8.9018.9x|5.3%
FCF FY+3
$10.316.4x|6.1%
FCF FY+4
$11.215.1x|6.6%
FCF FY+5
$12.513.4x|7.5%

Summary

AZN Valuation & Price Targets

Favorite Valuation Methods

PEvaluation
Analyst targets
DCF (2-stage)

More Valuation Methods

DCF (simple)
DCF (exit mult.)
DDM
EPS growth
Revenue growth
Peter Lynch FV
Graham No.

PEvaluation

CURRENT PRICE
$168
35% Overvalued
BEAR
BASE
BULL
Fair P/E
Margin of safety
EPS
Market Model
ROICRevenue growthFCF MarginShares outstan...Debt/EquityDebt/EBITDA
Economic moat: None/narrow

EPS Estimates

LowAvgHigh#
FY+110.010.310.624
FY+210.911.412.124
FY+311.412.713.920
FY+411.914.416.111
FY+512.316.018.611

Analyst Price Targets

CURRENT PRICE
$168
100% Overvalued
BEAR
BASE
BULL

Analyst Recommendations

Strong Buy6
Buy14
Hold3
Sell2
Strong Sell0

2-stage DCF

First Stage Duration: 5 Years
Starting Free Cash Flow
First Stage Growth Rate
Low
Mid
High
Terminal Growth Rate
Low
Mid
High
Discount Rate

Discounted Cash Flow

Forecast years: 5 Years
Terminal Growth Rate
Low
Mid
High
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Discounted Cash Flow (exit mult.)

Forecast years: 5 Years
Exit FCF Multiple
Low
Mid
High
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Dividend Discount Model

Annual Dividend
First Stage Length (Years): 0 Years
First Stage Growth Rate
Low
Mid
High
Final Growth Rate
Low
Mid
High
Discount Rate

EPS Growth

Forecast years: 5 Years
Starting EPS
EPS Growth Rate
Low
Mid
High
Final P/E
Low
Mid
High
Discount Rate

Revenue Growth Valuation

Forecast Years: 10 Years
Base Revenue
Revenue Growth Rate
Low
Mid
High
Final Net Margin
Low
Mid
High
Final P/E Ratio
Low
Mid
High
Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate
Low
Mid
High

Graham Formula

Earnings Per Share
EPS Growth (7-10 years)
Low
Mid
High
Government Bond Rate

Growth Estimates

Revenue

CAGR5.9%
TTMFY+1FY+2FY+3FY+4FY+5
TTM
$61.37(B)
FY+1
26
3%
$63.30(B)
FY+2
27
6%
$66.90(B)
FY+3
23
7%
$71.34(B)
FY+4
14
7%
$76.39(B)
FY+5
15
7%
$81.72(B)

Net Income

CAGR19.2%
TTMFY+1FY+2FY+3FY+4FY+5
TTM
$10.45(B)
FY+1
22
52%
$15.88(B)
FY+2
23
12%
$17.72(B)
FY+3
19
11%
$19.73(B)
FY+4
10
15%
$22.59(B)
FY+5
10
11%
$25.15(B)

EPS

CAGR18.9%
TTMFY+1FY+2FY+3FY+4FY+5
TTM
$6.74
FY+1
24
53%
$10.28
FY+2
24
11%
$11.44
FY+3
20
11%
$12.70
FY+4
11
13%
$14.39
FY+5
11
11%
$16.03

FCF per share

CAGR12.7%
TTMFY+1FY+2FY+3FY+4FY+5
TTM
$6.88
FY+1
11
18%
$5.65
FY+2
11
58%
$8.90
FY+3
11
15%
$10.26
FY+4
6
9%
$11.17
FY+5
6
12%
$12.53

Historical Financials (in USD)

Income(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.010.0(B)20.0(B)30.0(B)40.0(B)50.0(B)
Revenue Operating Income Net IncomeCOGSGross ProfitTotal OpEx.R&DSG&AInterest ExpenseInterest IncomeOther Non-operating IncomePre-tax incomeIncome tax
Cash flow(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.02.0(B)4.0(B)6.0(B)8.0(B)10.0(B)12.0(B)
Stock-based Comp. FCFCFONet IncomeD&AChange in Working CapitalCFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures
Balance sheet(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.020.0(B)40.0(B)60.0(B)80.0(B)100.0(B)
Total Assets Total LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EIntangible AssetsGoodwillCurrent liabilitiesShort-Term DebtAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity
Per share data(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.01.02.03.04.0
EPS (Basic) FCF/Share Dividend/ShareEPS (Diluted)Book value/ShareCash & ST inv./ShareDebt/Share
Ratios(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.020.040.060.080.0100.0
P/E P/S EV/EarningsP/FCFP/BDebt/EquityPayout ratio
Margins(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0%20%40%60%80%
Net Income Margin Operating Margin Gross MarginEBITDA Margin
Returns(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0%2%4%6%8%10%
ROIC ROAROCEROE
Shares outstanding(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.0500.0(M)1.0(B)1.5(B)2.0(B)2.5(B)3.0(B)
Shares (Basic)Shares (Diluted)
Market Cap.(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.050.0(B)100.0(B)150.0(B)200.0(B)
Market Cap.

AZN vs Peers

Similar Companies

Ownership

Major holders

*Excludes indirect insider ownership

Insiders: 0.05%
Institutions: 64.87%
Other: 35.08%

Institutional ownership

3.33% Investor AB2.93% Vanguard Capital Manag...2.23% Capital International ...2.18% NORGES BANK1.94% Capital World Investor...1.86% FMR, LLC1.84% Wellington Management ...1.66% Legal & General Group ...1.24% JPMORGAN CHASE & CO1.21% Vanguard Asset Managem...44.45% Others

Trading Summary

In the past year, insiders have sold a net of $53622.

Total insider buys: $0.00
Total insider sells: $53622

In the past year, Congress members have bought a net of $8001.

Total congressional buys (avg): $32002
Total congressional sells (avg): $24002

Based on the reported ranges: buys $4004–$60000, sells $3003–$45000.

Insider transactions

$0.002026-10$0.00
$0.002026-09$0.00
$0.002026-08$0.00
$0.002026-07$0.00
$0.002026-06$0.00
$0.002026-05$0.00
$0.002026-04$0.00
$0.002026-03$0.00
$0.002026-02$0.00
$0.002026-01$0.00
$536222025-12$0.00
$0.002025-11$0.00
$0.002025-10$0.00
DateSharesTotal ($)Price ($)NameTitle
Sell2025-12-1829753,622180.5Rahman (Nazneen)

Congressional trading

$0.002026-10$0.00
$0.002026-09$0.00
$0.002026-08$0.00
$0.002026-07$0.00
$0.002026-06$0.00
$0.002026-05$0.00
$0.002026-04$0.00
$0.002026-03$0.00
$0.002026-02$0.00
$0.002026-01$0.00
$0.002025-12$16001
$0.002025-11$8001
$80012025-10$8001
DatePoliticianPartyChamberAmount ($)
Buy2025-12-18Gilbert Ray Cisneros, Jr.DHouse$1,001 - $15,000
Buy2025-12-08Julia LetlowRHouse$1,001 - $15,000
Buy2025-11-19Gilbert Ray Cisneros, Jr.DHouse$1,001 - $15,000
Sell2025-10-31Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-10-21Gilbert Ray Cisneros, Jr.DHouse$1,001 - $15,000
Sell2025-09-23Val T. HoyleDHouse$1,001 - $15,000
Sell2025-09-23Val T. HoyleDHouse$1,001 - $15,000

Tools

Dividend Income

Investment Amount
Dividend Yield
What is the Dividend Income Calculator?

The Dividend Income Calculator helps you estimate the yearly, quarterly, monthly, and daily income of your investments.

How to Use This Calculator?

Enter the dividend yield and the invested amount. Optionally, preload stock data to automatically fetch the dividend yield.

Required Investment

Dividend Yield
Desired Yearly Payout
Desired Quarterly Payout
Desired Monthly Payout
What is the Required Investment Calculator?

The Required Investment Calculator helps you determine the amount of money you need to invest in a stock to achieve a desired dividend.

How to Use This Calculator?

Enter the dividend yield and your desired dividend income. Optionally, preload stock data to automatically fetch the dividend yield.

Future Dividend Yield

Base Dividend
Current Price
Number of Years
Dividend Growth Rate
What is the Future Yield Calculator?

The Future Yield Calculator helps you estimate the future dividend yield of a stock based on its current dividend, price, and expected dividend growth rate.

How to Use This Calculator?

Enter the base dividend, current price, number of years, and dividend growth rate. Optionally, preload stock data to automatically fetch the dividend and price. The calculator will display the current yield and the projected future yield.

Future Dividend Income

Base Dividend
Number of Years
Dividend Growth Rate
What is the Future Dividend Income Calculator?

The Future Dividend Income Calculator helps you estimate the future dividend income from your investments based on the current dividend yield and expected growth rate.

How to Use This Calculator?

Enter the current dividend yield, expected growth rate, and investment duration. Optionally, preload stock data to automatically fetch the dividend yield.